Egis Pharmaceuticals

To see an up-to date selection of historical analyses and insights on Egis Pharmaceuticals, visit our new, dynamically updated Company Summary report pages for Egis Pharmaceuticals.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for Egis Pharmaceuticals are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Egis Pharmaceuticals, or on any other Company covered by EvaluatePharma® Contact Us today.

CONSENSUS FORECASTS ($US mln) -  Sales Forecasts available to EvaluatePharma Subscribers
  Annual Sales WW - Sales Growth per Year (%)
  Rank Product Generic Name Pharmacological Class 2006 2007 2007
Egis Pharmaceuticals 1 Coverex perindopril erbumine ACE inhibitor 25 34   32%  
  2 Suprastin chloropyramine Anti-histamine 27 32   18%  
  3 Betaloc metoprolol tartrate Beta blocker 22 26   17%  
 
  Note: Shaded Cells  

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers
 
  Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current)
Egis Pharmaceuticals - Olanzapine Central Nervous System Anti-psychotics Atypical anti-psychotic Filed

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
Egis Pharmaceuticals
  2005 2006
 Valuation Measures
  Based on Latest Share Prices
     Valuing the Equity
       Market Capitalisation 427 427
       PE Ratio (diluted) - Normalised (x) 7.4 6.5
 
     Valuing the Enterprise
       Enterprise Value 350 350
       Free Cash Flow (Pre-Dividends) 16 17
       FCF Yield (%) 4.6% 4.8%
 
 Forecast Financials
  Income Statement
     Total Revenues 366 419
     Cost of Goods Sold (140) (145)
     S,G & A (129) (151)
     R&D (27) (31)
     Other Income/ Expense - Net (14) (27)
     Associate/ Equity Affiliate Income 2 3
     EBIT - Normalised 58 69
     Net Interest & Financial Items 7 7
     Pre-tax Profits - Normalised 65 76
     Exceptionals 0 0
     Income Before Taxes 64 75
     Tax (7) (9)
     Tax Rate (%) 11.2% 12.6%
     Net Income - Reported 57 66
     Net Income - Normalised 58 66
 
  Per Share Data
     EPS - Diluted 7.34 8.45
     EPS - Basic 7.34 8.45
     EPS - Normalised (diluted) 7.39 8.48
     EPS - Normalised (basic) 7.39 8.48
     Avg. Shares Outstanding - Diluted 7.8 7.8
     Avg. Shares Outstanding - Basic 7.8 7.8
     DPS 0.00 0.00

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
 
  Product Generic Name
Egis Pharmaceuticals Adexor trimetazidine
  Andaxin meprobamate
  Auronal felodipine
  Betadine iodine
  Betaloc metoprolol tartrate
  Bioparox fusafungine
  Cardilopin amlodipine besylate
  Cordaflex nifedipine
  Coverex perindopril erbumine
  Cytonin ciprofloxacin
  Deramciclane deramciclane fumarate
  Dopegyt methyldopa
  Dormicum midazolam
  Duellin carbidopa & levodopa
  Egis-11150 -
  Floxet fluoxetine
  Fludilat bencyclane
  Frontin alprazolam
  Grandaxin tofisopam
  Halixol ambroxol
  Ipaton ticlopidine
  Kaldyum potassium chloride
  Lidocain lidocaine
  Lucetam piracetam
  Milurit allopurinol
  Nitromint nitroglycerin
  Nofung fluconazole
  Olanzapine olanzapine
  Pidezol zolpidem
  Pipolphen promethazine
  Setegis terazosin
  Sorbifer Durules ferrous sulfate
  Stimuloton sertraline
  Sumetrolim sulfamethoxazole & trimethoprim
  Suprastin chloropyramine
  Talliton carvedilol
  Telviran acyclovir
  Tenaxum rilmenidine
  Tensiomin captopril
  Tisercin methotrimeprazine
  Vasilip simvastatin
  Vitamin C ascorbic acid
  Zitazonium tamoxifen

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.